Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 11,574 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Diabetic Foot Ulcer
Interventions: Corlicyte; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis (Diagnosis)
Interventions: Mepolizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Congestive Heart Failure, Cancer, Chronic Obstructive Pulmonary Disease, Cerebrovascular Accident, Frail Elderly Syndrome, Cardiovascular Diseases
Interventions: Serious Illness Care Program (SICP); Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 1,120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 5
States / cities: Aurora, Colorado • Iowa City, Iowa • Durham, North Carolina + 2 more

Conditions: Chronic Pain, Musculoskeletal Pain
Interventions: Posturographic evaluation; Other
Lead sponsor: Carrick Institute for Graduate Studies; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Savannah, Georgia

Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
Interventions: SelfWrap Bioabsorbable Perivascular Wrap, Untreated AVF Control; Device · Procedure
Lead sponsor: VenoStent; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 28
States / cities: Bullhead City, Arizona • Marana, Arizona • Phoenix, Arizona + 24 more

Conditions: Chronic Hepatic, Liver Diseases
Interventions: EUS-guided liver biopsy at MDMC; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Heart Failure, Congestive
Interventions: Case management using advanced nurse practitioners; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 4
States / cities: Danville, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more

Conditions: Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Remote Visit; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hyperkalemia
Interventions: Patiromer, Placebos; Drug
Lead sponsor: Vifor Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 133
States / cities: Alexander City, Alabama • Huntsville, Alabama • Phoenix, Arizona + 110 more

Conditions: Cerebral Palsy
Interventions: Clinical Assessments, Brain-Spinal Cord fMRI, Hoffmann Reflex Assessments, MEG Imaging, Transcutaneous Current Stimulation; Behavioral
Lead sponsor: Father Flanagan's Boys' Home; Other
Eligibility: 11 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boys Town, Nebraska

Conditions: Leukemia
Interventions: therapeutic autologous lymphocytes, cyclophosphamide; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Disease, Quality of Life
Interventions: Expanded Population Health Model; Behavioral
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dementia, Chronic Pain
Interventions: PICT Workbook, Information Pamphlet; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 100 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia
Interventions: DTGM; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stroke, Chronic Conditions
Interventions: Self- management program, Standard care; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies
Interventions: LBH589; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Post-acute Sequelae of SARS-CoV-2 Infection
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Lymphocytic Leukemia
Interventions: ABT-263; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 6
States / cities: La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: Chronic Kidney Disease; Iron Deficiency Anemia
Interventions: Ferumoxytol, Iron sucrose; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 8
States / cities: Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more

Conditions: Chronic Venous Disease
Interventions: Anti-embolism Knee High Stocking, 20-30 Knee High Compression Stocking; Device
Lead sponsor: BSN Medical Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: West Roxbury, Massachusetts

Conditions: Chronic Lymphocytic Leukemia
Interventions: Umbralisib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, WEE1 Inhibitor AZD1775; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Search by objective public record fields.

PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS

The Role of IL5 in Epithelial Cell Integrity

Team-based Versus Primary Care Clinician-led Advance Care Planning in Practice-based Research Networks

Posturographic Characteristics of Eccentric, Isometric and Concentric Movements

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

Efficacy, Safety, and Adequacy of EUS-guided Liver Biopsy

Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients

Evaluation of a Nurse Case Management Model for Chronic Heart Failure

Remote Physician Care for Home Hospital Patients

Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)

Neuromodulation of the Cortex and Spinal Cord

Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Expanded Population Health Model Evaluation

Developing a Pain Identification and Communication Toolkit

Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)

Feasibility of a Stroke Specific Self-management Program

A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589

Cognitive-Sensorimotor Function in Long-COVID

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Compression Aided Management of Edema in Patients With C3 Venous Disease

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome